Literature DB >> 789246

[Antimicrobial effectiveness of sisomicin. I: In vitro activity of sisomicin compared with gentamicin, tobramycin, amikacin and kanamycin (author's transl)].

H H Schassan.   

Abstract

The aminoglycosides sisomicin, gentamicin, tobramycin, amikacin and kanamycin are highly active against staphylococci including the penicillinase-positive strains. Sisomicin is more effective than amikacin and kanamycin. Mixed infections with staphylococci and Enterobacteriaceae or Pseudomonas aeruginosa are thus on indication for treatment with sisomicin or other aminoglycosides. Infections with E. coli, Enterobacter, susceptible Klebsiella, and susceptible Pseudomonas strains can be treated with sisomicin, gentamicin or tobramycin. In such cases sisomicin is the most effective antibiotic because of its high antimicrobial activity. In infections with these organisms amikacin can also be used for treatment especially if there is resistance to other aminoglycosides. In hospital-acquired infections with Serratia marcescens amikacin and sisomicin are the drugs of choice. Both aminoglycosides have to be given in high doses in infections with Serratia because of the high inhibitory concentration for Serratia. Sisomicin demonstrates a high antimicrobial activity particularly against indole-positive Proteus species such as Proteus vulgaris and Proteus morganii, Enterobacter, and gentamicin-sensitive Pseudomonas strains. In infections with Pseudomonas aeruginosa tobramycin is the most effective bactericidal antibiotic. Amikacin is the drug of choice against gentamicin-resistant Pseudomonas strains which are also not infrequently resistant to other aminoglycosides. The low proportion of resistance to sisomicin of 7,6% in 370 organisms is only exceeded by amikacin with a rate of 0,6% (resistance to tobramycin 11,4%, gentamicin, 13,2% and kanamycin 42,4%). The low rate of resistance and the high antimicrobial activity are essential advantages of sisomicin.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 789246     DOI: 10.1007/bf01638346

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  11 in total

1.  Antistaphylococcal activity of sisomicin and four other aminoglycosides against strains sensitive and resistant to methicillin.

Authors:  E Yourassowsky; E Schoutens; M P Vanderlinden
Journal:  Infection       Date:  1975       Impact factor: 3.553

2.  Antibiotic sensitivity testing. Report of an international collaborative study.

Authors:  H M Ericsson; J C Sherris
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1971

3.  Is there complete cross-resistance of gram-negative bacilli to gentamicin and tobramycin?

Authors:  C C Crowe; E Sanders
Journal:  Antimicrob Agents Chemother       Date:  1972-11       Impact factor: 5.191

4.  Antibiotic 6640, a new Micromonospora-produced aminoglycoside antibiotic.

Authors:  M J Weinstein; J A Marquez; R T Testa; G H Wagman; E M Oden; J A Waitz
Journal:  J Antibiot (Tokyo)       Date:  1970-11       Impact factor: 2.649

5.  Antipseudomonal drugs: comparative study of gentamicin, sisomicin and tobramycin in vitro and in human volunteers.

Authors:  J Klastersky; A Henri; C Hensgens; L Vandenborre; D Daneau
Journal:  Eur J Cancer       Date:  1973-09       Impact factor: 9.162

6.  Comparative activity of sisomicin, gentamicin, kanamycin, and tobramycin.

Authors:  J A Waitz; E L Moss; C G Drube; M J Weinstein
Journal:  Antimicrob Agents Chemother       Date:  1972-12       Impact factor: 5.191

7.  Activity of BB-K8 (amikacin) against clinical isolates resistant to one or more aminoglycoside antibiotics.

Authors:  K E Price; T A Pursiano; M D DeFuria
Journal:  Antimicrob Agents Chemother       Date:  1974-02       Impact factor: 5.191

8.  Sisomicin: evaluation in vitro and comparison with gentamicin and tobramycin.

Authors:  C C Crowe; E Sanders
Journal:  Antimicrob Agents Chemother       Date:  1973-01       Impact factor: 5.191

9.  Activity of five aminoglycoside antibiotics in vitro against gram-negative bacilli and Staphylococcus aureus.

Authors:  L S Young; W L Hewitt
Journal:  Antimicrob Agents Chemother       Date:  1973-12       Impact factor: 5.191

10.  In vitro bactericidal effectiveness of four aminoglycoside antibiotics.

Authors:  P J Hyams; M S Simberkoff; J J Rahal
Journal:  Antimicrob Agents Chemother       Date:  1973-01       Impact factor: 5.191

View more
  4 in total

Review 1.  Tobramycin: a review of its antibacterial and pharmacokinetic properties and therapeutic use.

Authors:  R N Brogden; R M Pinder; P R Sawyer; T M Speight; G S Avery
Journal:  Drugs       Date:  1976       Impact factor: 9.546

2.  [Concentration in bone and haematoma of the aminoglycoside antibiotic tobramycin (author's transl)].

Authors:  W Winkelmann; K P Schulitz; H Knothe; B Schoening
Journal:  Infection       Date:  1978       Impact factor: 3.553

3.  [Pharmacokinetic and clinical studies with sisomicin in paediatrics (author's transl)].

Authors:  M Doerck; G Fricke; G Gruenwaldt; H M von Hattingberg; M Scheer
Journal:  Infection       Date:  1980       Impact factor: 3.553

4.  Formulation of Antimicrobial Tobramycin Loaded PLGA Nanoparticles via Complexation with AOT.

Authors:  Marcus Hill; Richard N Cunningham; Rania M Hathout; Christopher Johnston; John G Hardy; Marie E Migaud
Journal:  J Funct Biomater       Date:  2019-06-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.